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Chronic diseases such as cancer, cardiovascular disease,
stroke, and diabetes are responsible for most deaths in the
United States. Lifestyle factors — poor nutrition, seden-
tary living, and tobacco use — appear to play a prominent
role in the development of many chronic diseases. This
study determined the behavioral and clinical impact of a
therapeutic lifestyle-modification intervention on a group
of community volunteers.
Methods
Participants included 348 volunteers aged 24 to 81 years
from the Rockford, Ill, metropolitan area who participated
in a randomized clinical trial. The intervention group
attended a 40-hour educational course delivered as lec-
tures during a 4-week period. Participants learned the
importance of making better lifestyle choices and how to
make improvements in nutrition and physical activity.
Changes in nutrition, physical activity behavior, and sev-
eral chronic disease risk factors were assessed at baseline
and 6 months.
Results
Intervention participants showed significant 6-month
improvement in all nutrition and physical activity meas-
ures except calories from protein and whole-grain servings
and all clinical measures except blood glucose, total 
cholesterol, triglycerides, and high-sensitivity C-reactive
protein. Total cholesterol and low-density lipoprotein cho-
lesterol were worse after 6 months in both groups but only
significantly worse in the control group. The control group
experienced small but significant improvements in systolic
and diastolic blood pressure and high-density lipoproteins.
Change-score comparisons between the intervention and
control groups were significant for all nutrition and physi-
cal activity variables except total steps per week and daily
sodium intake and were also significant for the clinical
measures of weight, body fat, and body mass index.
Conclusion
This therapeutic lifestyle-modification program can sig-
nificantly improve nutrition and physical activity behavior
and can reduce many of the risk factors associated with
common chronic diseases.
Introduction
Chronic diseases such as cancer, cardiovascular disease,
stroke, and diabetes are responsible for most deaths in the
United States (1). Between 70% and 90% of these deaths
are believed to be caused by poor nutrition, sedentary liv-
ing, and tobacco use and are preventable (2-4). These
lifestyle factors appear to play a prominent role in the
mechanisms and processes that lead to the development of
many chronic diseases. The largest reductions in chronic
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disease prevalence in the United States will be achieved
when individuals adopt and maintain lifestyles that
include a healthy diet and regular physical activity.
During the 1980s, Nathan Pritikin conducted several in-
patient lifestyle-change programs that documented how a
low-fat, high–complex-carbohydrate, high-fiber diet and
regular exercise could improve blood lipid levels and insulin
sensitivity (5-7). Variations of this holistic approach to pre-
venting and arresting chronic diseases have more recently
been evaluated in randomized clinical trials such as the
PREMIER clinical trial (8), the DASH dietary study (9),
and other trials in the United States, United Kingdom, and
New Zealand (10-12). Most of these trials used inpatient
treatment or controlled feeding to encourage and monitor
changes in diet and physical activity. All of them demon-
strated reductions in cardiovascular risk factors, including
obesity, blood pressure, and blood lipid levels.
The Coronary Health Improvement Project (CHIP) was
created with the goal of reducing chronic diseases and
improving the overall health of the public by providing a
lifestyle-change program to both the community and the
workplace (13). The CHIP is a 40-hour live-lecture educa-
tional course that highlights the importance of making
better lifestyle choices for reducing chronic disease risk
factors. A one-group pretest–posttest analysis of the 
program revealed that after 4 weeks, participants signifi-
cantly reduced their blood pressure, blood glucose, body
weight, and total and low-density lipoprotein (LDL) cho-
lesterol (13). This exploratory study demonstrated that the
program had the potential to improve not only coronary
risk factors but also the risks associated with cancer, dia-
betes, and the metabolic syndrome. These results were
repeated in a quasi-experimental design that included
results from six groups of working adults (14).
A large randomized clinical trial was initiated to further
explore the effect of the CHIP (15). Six-week results from
this study revealed that adults who completed the pro-
gram improved their nutrition and physical activity behav-
ior and reduced cardiovascular disease risk factors (15).
We present the behavioral and clinical changes that par-
ticipants in this therapeutic lifestyle-change program
experienced after 6 months.
Methods
Subject recruitment and study design
Recruitment was conducted by the SwedishAmerican
Center for Complementary Medicine (SACCM) using 
targeted advertising, marketing through the
SwedishAmerican Health System Centers of Excellence,
CHIP alumni groups, corporate client sites, and the
SwedishAmerican Health System. Recruitment efforts
were aimed at adults (aged at least 18 years) in the greater
Rockford, Ill, metropolitan area. To be enrolled in the
study, each participant had to be willing to start partici-
pating in the program in 1 month or in 7 months. Figure 1
shows participant progress through the study. Eligible and
interested participants provided informed consent.
Participants were highly encouraged to participate with a
spouse or significant other and were randomized as a
paired unit. All other participants were randomized as
individual units. The allocation sequence was created
using a random number generator. Program sign-up, ran-
domization, and group assignments were made by the
study coordinator. The study was approved by the
Institutional Review Board of the SwedishAmerican
Health System on August 29, 2002.
Intervention
The intervention for this study was a live version of the
CHIP (13). Participants met for 4 weeks — 4 times each
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Figure 1. Process for a therapeutic lifestyle-modification intervention with a
group of community volunteers, Rockford, Ill.
week for 2 hours — to receive instruction during April
2003. The curriculum included the following topics: mod-
ern medicine and health myths, atherosclerosis, coronary
risk factors, obesity, dietary fiber, dietary fat, diabetes,
hypertension, cholesterol, exercise, osteoporosis, cancer,
lifestyle and health, the Optimal Diet, behavioral change,
and self-worth.
In conjunction with CHIP lectures, participants received
a textbook and workbook that closely followed the curricu-
lum topics and included assignments with learning objec-
tives for every topic. Copies of these materials can be
obtained from CHIP at www.chipusa.org*. Assignments
were designed to help participants understand and inte-
grate the information presented. Dietitians and medical
professionals spoke to the group weekly, introducing them
to the latest nutritional and medical information related to
the prevention of chronic diseases. Participants had access
to scheduled shopping tours and cooking demonstrations
given by a dietitian.
The diet guidelines approximate the recommendations
previously used in the Pritikin program (5-7), and the exer-
cise guidelines are from the Surgeon General’s Report on
Physical Activity and Health (16). Participants were
encouraged to follow preset dietary and exercise goals. The
dietary goal was to adopt a more plant-food–based diet
that emphasizes as-grown, unrefined food. Participants
were encouraged to eat the following foods: whole grains,
legumes, vegetables, and fresh fruits. In addition, the diet
was low in fat (less than 20% of energy), animal protein,
sugar, and salt; very low in cholesterol; and high in fiber.
Concurrently, program participants were encouraged to
work toward walking or exercising for at least 30 minutes
each day. Participants were given a pedometer and encour-
aged to keep an exercise log to record the miles walked
each day. In addition, at the completion of the program,
participants were encouraged to join the Rockford CHIP
alumni association for an annual cost of $25 for an indi-
vidual or $35 for a couple. The purpose of the alumni
organization was to help prevent relapse and help partici-
pants maintain their new behaviors. Alumni receive a
monthly newsletter that contains news of health-promot-
ing community events such as healthy dinners, walking
groups, and support-group meetings. The alumni were
encouraged to attend special lectures on healthy living and
ways to avoid relapse. 
The primary objectives of this therapeutic lifestyle-
change program were to improve cognitive understanding
of the importance of healthy lifestyles, nutrition, and phys-
ical activity behavior and reduce risk factors associated
with hypertension and cardiovascular disease. The cost to
participate in the entire CHIP was $395 per person or $595
per couple.
Measures
Variables gathered included cognitive and behavioral
measurements and physiologic outcomes related to chron-
ic disease. Demographic data were collected at baseline in
April 2003. Attendance at each of the classes was tracked
and averaged. Participants attended an average of 89% of
the classes.
The intervention was designed to assist individuals in
adopting healthy eating and physical activity behaviors.
To assess dietary intake, the Block 98 full-length dietary
questionnaire was used (Block 98.2, Block Dietary Data
Systems, Berkeley, Calif). The Block 98 questionnaire has
been extensively studied and validated (17). The question-
naire contains self-reported data and is optically scanned
and scored. The questionnaire measures the following
variables (in addition to others) on a per-day basis: nutri-
ents obtained from food; percentage of calories from fats,
carbohydrates, and protein; fiber from different sources;
and food group servings per day.
To ascertain energy expenditure contributed by physical
activity, a 7-day self-recorded pedometer log was main-
tained by each participant. Participants wore the
Walk4Life Model 2000 Life Stepper pedometer (Walk4Life
Inc, Plainfield, Ill) on a belt at the right hip directly above
the right kneecap each day for 7 days. Immediately before
going to bed, participants recorded the number of steps for
the day and reset the pedometer. Strike counts from
pedometers are a valid and reliable method of monitoring
and measuring free-living physical activity (18).
The primary outcome variables for this study included
several chronic disease risk factors. The following data
were collected from April to October 2003. Blood was
drawn from participants (after a 12-hour fast) by phle-
botomists from the SwedishAmerican Health System’s
outpatient laboratory using a vacutainer (Becton-
Dickinson Vacutainer Systems, Rutherford, NJ). Samples
were allowed to clot and were centrifuged. Clinical analy-
ses were completed at the SwedishAmerican Health
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System laboratory. Lipid analysis followed the lipid stan-
dards provided by the Centers for Disease Control and
Prevention. Glucose, total cholesterol, high-density
lipoprotein (HDL), and triglyceride concentrations were
determined using Beckman-Coulter LX-20 instrumenta-
tion (Beckman Coulter, Inc, Fullerton, Calif). Glucose
measurements were obtained with the oxygen-rate
method using a Beckman oxygen electrode; cholesterol
measurements were obtained with the timed-endpoint
enzymatic method using cholesterol oxidase; triglyceride
measurements were obtained with the timed-endpoint
enzymatic method using glycerol kinase; and HDL meas-
urements were obtained with the homogeneous timed-
endpoint method using polyanion detergent to separate
HDL and non-HDL lipids. For participants with triglyc-
eride values below 400, LDL values were calculated as
follows: LDL = total cholesterol – HDL – (triglycerides/5)
(19). High-sensitivity C-reactive protein (CRP) measure-
ments were determined using a microplate protocol based
on a latex-bead–enhanced immunoturbidity assay (20).
Glucose measurements were determined using a Kodak
Ektachem (Kodak, Rochester, NY). Trained program staff
took blood pressure measurements. Blood pressure was
measured in participants after a 5-minute rest, using the
guidelines set forth by the American Heart Association.
Weight and height were measured using standard medical
weight and height scales recently calibrated by the bio-
metrics department of the SwedishAmerican Health
System. Percentage of body fat was estimated with Tanita
TBF-300A Body Composition Analyzer/Scale using bioelec-
trical impedance analysis (Tanita, Tokyo, Japan) (21).
Body mass index (BMI) was determined using the follow-
ing formula: weight (kg)/height (m2).
Statistical analyses
Cross-tabulations were used to perform bivariate analy-
ses between selected variables, with statistical significance
based on the chi-square test for independence. For testing
differences in means, t tests were used. Because multiple
pair-wise tests were performed, an adjusted α was used to
minimize the overall probability of committing a type I
error. The modified α is .0001, based on the Bonferroni cor-
rection, 28 pair-wise tests, and α = .05. This conservative α
was used to determine significance for data in Tables 2
through 7. Risk factor cut-points (Tables 6 and 7) were pre-
viously established (22,23) and categorized accordingly.
Results are based on the intent-to-treat method in which
all participants were retained in the analyses. Where par-
ticipant data were lost to follow-up, the last-test carry-for-
ward method was applied to the participant’s most recent
data. The results did not differ significantly when partici-
pants lost to follow-up were dropped from the analyses.
These results are not reported. Analyses were performed
using SAS 9.0 (SAS Institute Inc, Cary, NC). Procedure
statements used in SAS for assessing the data were PROC
UNIVARIATE, PROC FREQ, PROC TTEST, and PROC
GLM.
Results
There were 318 participants who completed both base-
line and 6-month evaluations. An additional 30 completed
the baseline evaluation but not the 6-month evaluation. Of
these lost to follow-up, 21 were in the intervention group,
and 9 were in the control group (Figure 1).
Analyses were based on 348 participants. Ages ranged
from 24 to 81 years, with little difference in the mean age
between intervention and control groups (50.1 years, inter-
vention group; 50.8 years, control group, t346 = –0.57, P =
.57). A description of participants in both intervention and
control groups is presented according to selected 
demographic characteristics in Table 1. There were no sta-
tistically significant differences between groups for these
variables. Within each group, the majority of participants
had the following characteristics: female, white, married,
an annual family income of at least $60,000, and at least
some college education. Of the intervention participants,
47 (27%) joined the CHIP alumni association.
Because the unit of randomization was pairs for those
who participated with a partner and individuals for
those who participated as individuals, comparisons
were made of the effect of the program between pairs
and individuals. Of the 348 randomized participants,
146 (42%) participated as pairs. There were no signifi-
cant differences in the outcomes of pairs and individu-
als. After 6 months, participants in the intervention
group experienced significant improvements in all phys-
ical activity and nutrition variables except calories from
protein and whole-grain servings (Table 2). Changes in
the control group were generally not statistically signif-
icant, or they were much smaller in magnitude than the
changes in the intervention group. For each variable
except total steps per week and daily sodium intake, the
change observed in physical activity or nutrition was
4 Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2006/jan/05_0088.htm
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only
and does not imply endorsement by any of the groups named above.
significantly greater for participants in the intervention
group compared with the control group (Table 3). The con-
trol group consumed significantly more fat calories and
fewer whole-grain servings at 6-month follow-up compared
with the control group at 6-month follow-up.
After 6 months, participants in the intervention group
showed significant reductions in BMI, weight, body fat,
systolic and diastolic blood pressure, and resting heart rate
(Table 4). The control group experienced significant
improvements in systolic and diastolic blood pressure and
HDL, but total cholesterol and LDL were significantly
worse. For BMI, weight, and body fat, changes were sig-
nificantly greater for participants in the intervention
group compared with the control group (Table 5).
Mean baseline, 6-month, and change in mean scores are
presented according to standard health risk cut-points for
the risk factor variables according to intervention group
(Table 6) and control group (Table 7). This analysis strati-
fies results according to risk status. Individuals with low
risk would not be expected to experience large changes, but
risk values considered to be high would be expected to
change significantly. For the intervention group, the dis-
tributions favorably changed between baseline and 6
months for BMI, systolic blood pressure, and diastolic
blood pressure. Corresponding significant change in the
distribution between baseline and 6 months was observed
in the control group for systolic blood pressure and dias-
tolic blood pressure but not for BMI. Favorable changes in
risk behaviors were generally higher and more likely to be
significant for individuals in the intervention group than
for individuals in the control group.
Whereas total cholesterol significantly increased
between baseline and 6 months for participants in the con-
trol group, no significant difference was observed in the
intervention group. For both intervention and control
groups, total cholesterol significantly increased among
participants with total cholesterol in the normal range and
decreased (but not significantly) for those with cholesterol
in the high-risk category. Cholesterol medication played a
minimal role in the change observed in cholesterol. At
baseline, there were 77 participants in the intervention
group who reported using blood pressure medication. At 6
months, 60 participants (75%) indicated no change in their
medication over the study period, 9 participants (11.2%)
indicated a dosage increase, and 11 participants (13.8%)
indicated a dosage decrease. There was not a significant
difference in the use of blood pressure medication from
baseline to 6 months between the intervention and control
groups (X21 = 1.14, P = .56).
Discussion
Therapeutic lifestyle change can result in significant
improvements in nutrition and physical activity behavior
and reductions in many cardiovascular disease risk fac-
tors. Six months after the intervention began, program
participants continued to demonstrate dramatic improve-
ments in nutrition and physical activity behavior.
Increases in the number of servings of fruit and vegetables
and whole grains, increases in physical activity, and
decreases in dietary sodium are likely responsible for the
improvements in both systolic and diastolic blood pressure.
Intervention group participants consumed 2.3 more serv-
ings of fruit and vegetables per day at 6 months compared
with baseline. In the PREMIER study (8), participants
who completed a behavior-change program and adopted
the DASH diet increased fruit and vegetable servings by
3.0 servings after 6 months. Those PREMIER program
participants decreased their percentage of calories from fat
by 9.5% and lost an average of 5.8 kg of body weight. This
compares to a percentage fat reduction of 8.2% and a 4.5 kg
weight loss for intervention participants in the present
study.
At baseline, the intervention group included 77 partici-
pants who were at least diastolic prehypertensive at 6
months; this number decreased by 44% to 43 participants
at 6 months (Table 6). The number of intervention-group
participants who were at least systolic prehypertensive at
baseline declined by 20%, from 122 participants at base-
line to 98 at 6 months. The average reductions in blood
pressure were greater than the reductions reported in the
DASH study (9) and comparable with the results of the
PREMIER clinical trial (8).
Previous reports of the CHIP intervention showed sharp
improvements in blood lipid levels at 6 weeks, but most of
these changes disappeared at 6 months (7). Other thera-
peutic lifestyle trials that lasted longer than 3 months 
and included lipid outcomes reported similar findings 
(10-12,24). In this study, dietary cholesterol among the
intervention group was reduced by 122 mg/day (a 56%
reduction), and dietary saturated fat was cut by half.
Despite these favorable changes in dietary cholesterol 
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precursors, a return to previous lipid levels suggests that
there is a significant increase in endogenous cholesterol,
most of which appears to be LDL cholesterol (25). It is also
possible that these changes in blood lipid levels were
affected by seasonal variation. Without more accurate
measures of endogenous cholesterol biosynthesis, it 
is impossible to determine the exact cause of the 
cholesterol increase (26).
Pedometer data show that program participants
increased physical activity by 30%. The average number of
steps for the intervention group after 6 months did not
meet the recommended 10,000 steps per day (27). For this
predominately middle-aged and obese population, howev-
er, an increase in physical activity of 30% likely con-
tributed to risk factor reductions. When combined with
diet changes, improvement in physical activity is the like-
ly explanation for the percentage decreases in BMI (–5%),
weight (–5%), and percentage body fat (–6%) among the
intervention group. Improved physical activity was also
associated with a significant decrease in resting heart rate,
a correlated measure of cardiorespiratory fitness thought
to be caused by increased heart size, blood volume, stroke
volume, and cardiac output (28).
Poor nutrition and sedentary living are associated with
a constellation of risk factors, some identified in the meta-
bolic syndrome, and all linked to common chronic diseases
(29). Improvements in nutrition and physical activity are
associated with significant reductions in diabetes risk as
whole body glucose tolerance improves, insulin sensitivity
increases, and the amount of glucose transporter (GLUT4)
increases (30). The number of individuals with diabetes
(glucose >126 mg/dL) in the intervention group was
reduced by 19%, demonstrating that this therapeutic
lifestyle-change program improves insulin sensitivity.
Similar results were reported by other lifestyle trials
reporting glucose findings (11,12).
These improvements in behavior and risk are not
unexpected because the intervention lectures were
structured on the health belief and transtheoretical
models. Video clips, testimonials, role playing, short
presentations from physicians, social support 
strategies, food selection and planning activities, and
other behavior-change–driven pedagogical activities
helped to encourage participants to enthusiastically
evaluate personal behaviors and commit to make
lifestyle changes.
Most of the participants were white and sufficiently
self-motivated to volunteer to participate in the inter-
vention. On average, participants were slightly more
educated than the community average. Participants
had lifestyles that permitted them to attend most, if
not all, of the classes. This is evident in the high rate of
attendance to this time-intensive program. These
delimitations threaten the generalizability of these
findings and make application of the intervention to
other populations problematic. Because the partici-
pants were self-selected, the results from this interven-
tion may represent a best-case scenario.
Despite the apparent effect of this intervention, there
are some shortcomings associated with the study
design. Both the physical activity and nutrition data
were self-reported. For some variables, the control
group also experienced significant improvement.
Significant decreases were observed in the control
group in percentage of fat calories and dietary-fat
grams, sodium grams, and total calories as well as
small increases in total steps. In addition, the control
group experienced similar improvement in blood pres-
sure compared with the intervention group. There are
more than 27 restaurants in the Rockford metropolitan
area that offer healthy, CHIP-recommended menu
items, which could have contributed to improvements
in the control group. When conducting lifestyle trials,
the question of what to do with the control group is dif-
ficult to answer because there is no such thing as a
lifestyle placebo. After participants were assigned to an
intervention or control group, some control-group par-
ticipants expressed happiness with their assignment
because they had personal or work-related conflicts
that would have prohibited them from participating in
the intervention group. Others were disappointed in
their control-group assignment but realized when they
agreed to participate in the research study that there
was always the chance that they would have to wait to
participate in the program.
This study indicates that an intervention that uses vari-
ous behavior modification tools, such as live lectures, work-
books, and professional advice, and is implemented among
a group of middle-aged volunteers can result in reduced
risk factors for cardiovascular disease after 6 months.
Further research is needed to examine the effects of the
program on other populations.
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Tables
Table 1. Comparison of Demographic Characteristics of Intervention and Control Groups in a Therapeutic Lifestyle-
Modification Program
Sex
Male 47 27.0 51 29.3 X21 = 0.2 (.63)
Female 127 73.0 123 70.7
Race
White 167 96.0 160 93.0 X22 = 2.9 (.23)
Black 4 2.3 10 5.8
Other 3 1.7 2 1.2
Marital status
Never married 12 6.9 20 11.6 X23 = 3.0 (.39)
Married 138 79.8 127 73.4
Divorced 16 9.2 16 9.2
Widowed 7 4.1 10 5.8
Annual family income, $
0–20,000 14 8.2 12 7.1 X23 = 1.0 (.79)
20,001–40,000 34 20.0 28 16.5
40,001–60,000 37 21.8 41 24.1
>60,000 85 50.0 89 52.3
Education
<High school 4 2.3 7 4.0 X24 = 6.6 (.16)
High school 37 21.5 46 26.6
Some college 58 33.7 39 22.5
College degree 39 22.7 38 22.0
Post-college degree 34 19.8 43 24.9
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Intervention Control
n = 174 n = 174
Characteristic No. % No. % X2df (P)
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Table 2. Physical Activity and Nutrition Variables at Baseline and 6-Month Follow-up Among Participants in a Therapeutic
Lifestyle-Modification Program
Total steps/week 40,579 52,951 12,372 9.11 43,869 49,530 5661 4.12 (<.0001)
(22,631) (24,240) (<.0001) (23,466) (22,544)
Kcal intake/day 2092 1534 –558 –9.45 1919 1773 –146 –3.35 (.001)
(1030) (691) (<.0001) (805) (777)
Fat kcal/day, % 36.7 28.5 –8.2 –13.96 34.6 35.6 1.0 1.92 (.06)
(6.9) (7.0) (<.0001) (7.4) (8.3)
Protein kcal/day, % 15.2 14.4 –0.8 –3.74 14.7 15.4 0.7 2.61 (.01)
(2.8) (2.2) (.0003) (2.5) (3.2)
Carbohydrates 48.7 59.2 10.5 15.38 50.8 49.4 –1.4 –2.41 (.02)
kcal/day, % (8.0) (8.5) (<.0001) (8.2) (9.6)
Fruit and vegetable 7.6 11.6 4.0 9.30 8.3 8.0 –0.3 –1.31 (.19)
fiber, g/day (4.3) (5.6) (<.0001) (5.0) (4.5)
Vegetable servings/day 3.3 4.7 1.4 7.24 3.4 3.5 0.1 0.44 (.66)
(2.1) (2.6) (<.0001) (2.2) (2.1)
Fruit servings/day 1.3 2.2 0.9 10.39 1.6 1.6 0 –0.39 (.69)
(1.0) (1.2) (<.0001) (1.1) (1.1)
Whole-grain servings/day 5.4 6.1 0.7 3.11 5.0 4.5 –0.5 –3.46 (.001)
(2.9) (3.2) (.002) (2.4) (2.3)
Meat servings/day 2.1 1.3 –0.8 –8.29 1.9 1.9 0 0.01 (.99)
(1.4) (1.0) (<.0001) (1.2) (1.1)
Dietary fat, g/day 88.6 50.6 –38.0 –12.15 76.8 71.9 –4.9 –2.19 (.03)
(55.3) (33.5) (<.0001) (42.9) (40.3)
Dietary cholesterol, 216 94 –122 –14.55 182 192 10 1.24 (.22)
mg/day (140) (90) (<.0001) (112) (140)
Polyunsaturated fat, 21.2 13.6 –7.6 –9.43 19.3 17.7 –1.6 –2.53 (.01)
g/day (14.0) (8.3) (<.0001) (12.0) (10.4)
Monounsaturated fat, 34.3 18.8 –15.5 –12.42 29.7 27.9 –1.8 –1.99 (.048)
g/day (21.6) (13.1) (<.0001) (17.2) (16.3)
Saturated fat, g/day 26.3 13.3 –13.0 –13.34 21.8 20.5 –1.4 –2.17 (.03)
(17.3) (10.5) (<.0001) (12.1) (12.0)
Sodium, mg/day 2941 2332 –609 –7.35 2712 2486 –226 –3.40 (.001)
(1530) (1216) (<.0001) (1233) (1135)
adf = 170 for all variables except total steps/week, for which df = 166.
bSignificance for P values was determined using the Bonferroni correction and set at α = .0001.
cdf = 171 for all variables except total steps/week, for which df = 169.
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Intervention Group (n = 174) Control Group (n = 174)
6-Month 6-Month 
Baseline Follow-up Baseline Follow-up
Mean Mean Mean Mean Mean Mean 
Variable (SD) (SD) Change ta(Pb) (SD) (SD) Change tc(Pb)
Table 3. Comparison of 6-Month Change in Mean Values for Nutrition and Physical Activity Variables Among Intervention-
Group (n = 174) and Control-Group (n = 174) Participants in a Therapeutic Lifestyle-Modification Program
Total steps/week 6711 (3026 to 10,396) t335 = 3.81 (.0002)
Kcal intake/day –412 (–556 to –271) t310 = –5.69 (<.0001)
Fat kcal/day, % –9.2 (–10.6 to –7.6) t329 = –11.98 (<.0001)
Protein kcal/day, % –1.5 (–2.1 to –0.8) t341 = –4.50 (<.0001)
Carbohydrates kcal, % 11.9 (10.1 to 13.6) t328 = 13.42 (<.0001)
Fruit and vegetable fiber, g/day 4.3 (3.3 to 5.3) t284 = 8.59 (<.0001)
Vegetable servings/day 1.3 (0.9 to 1.9) t302 = 5.72 (<.0001)
Fruit servings/day 0.9 (0.6 to 1.1) t337 = 8.01 (<.0001)
Whole-grain servings/day 1.2 (0.7 to 1.7) t310 = 4.55 (<.0001)
Meat servings/day –0.8 (–1.0 to –0.5) t341 = –6.23 (<.0001)
Dietary fat, g/day –33.1 (–40.6 to –25.7) t303 = –8.74 (<.0001)
Dietary cholesterol, mg/day –132 (–153 to –108) t341 = –11.35 (<.0001)
Polyunsaturated fat, g/day –6.0 (–8.1 to –4.1) t316 = –6.01 (<.0001)
Monounsaturated fat, g/day –13.7 (–16.6 to –10.6) t310 = –8.90 (<.0001)
Saturated fat, g/day –11.6 (–13.9 to –9.3) t290 = –10.06 (<.0001)
Sodium, mg/day –383 (–590 to –176) t322 = –3.69 (.0003)
aSignificance for P values was determined using the Bonferroni correction and set at α = .0001.
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Change in Mean Values 
Variable (95% Confidence Interval) tdf(P
a)
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Table 4. Health Risk Factors at Baseline and 6-Month Follow-up Among Participants in a Therapeutic Lifestyle-Modification
Program
Body mass index 33.3 31.7 –1.6 t172 = –11.53 31.4 31.1 –0.3 t172 = –3.01 
(8.0) (8.1) (<.0001) (9.0) (9.2) (.003)
Weight, kg 93.3 88.8 –4.5 t172 = –11.83 87.7 87.1 –0.6 t173 = –1.64 
(24.1) (24.0) (<.0001) (25.9) (26.0) (.10)
Body fat, % 40.6 38.2 –2.4 t172 = –8.20 37.9 37.1 –0.8 t172 = –3.20 
(8.8) (9.6) (<.0001) (10.3) (10.5) (.002)
Systolic blood pressure, 129 124 –5 t172 = –5.60 128 124 –4 t171 = –4.98 
mm Hg (16) (18) (<.0001) (17) (18) (<.0001)
Diastolic blood pressure, 78.3 72.8 –5.5 t172 = –8.35 76.7 72.9 –3.8 t172 = –6.49 
mm Hg (9.2) (9.7) (<.0001) (9.6) (9.7) (<.0001)
Resting heart rate, 73.1 69.6 –3.5 t167 = –5.30 72.1 70.8 –1.3 t167 = –1.52 
beats/min (10.2) (10.6) (<.0001) (10.6) (10.3) (.13)
Glucose, mg/dL 103 100 –3 t171 = –2.79 100 99 –1 t167 = –0.29 
(23) (20) (.006) (19) (22) (.77)
Cholesterol, mg/dL 193 199 6 t171 = 2.88 190 201 11 t167 = 4.81 
(33) (34) (.004) (39) (39) (<.0001)
High-density lipoprotein, 45.0 46.4 1.4 t171 = 2.70 45.0 47.8 1.8 t167 = 5.38 
mg/dL (12.2) (11.8) (.008) (10.4) (10.4) (<.0001)
Low-density lipoprotein, 122 127 5 t168 = 2.83 121 130 9 t166 = 4.12 
mg/dL (29) (29) (.005) (33) (34) (<.0001)
Triglycerides, mg/dL 133 128 –5 t171 = –0.91 115 117 2 t167 = 0.31 
(102) (78) (.37) (86) (69) (.76)
C-reactive protein, 283.0 217.5 –66.5 –1059.5 228.6 226.6 –2.0 –814
mg/dLb (2.6-1320.0) (0.2-419.0) (.06) (13.5-1356.8) (0.4-1354.5) (.17)
aSignificance for P values was determined using the Bonferroni correction and set at α = .0001. 
bC-reactive protein mean change scores violated the assumption of normality; thus, median and range scores are reported. The Wilcoxon signed rank test
was used to test for differences in medians within groups.
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Intervention Group (n = 174) Control Group (n = 174)
6-Month 6-Month 
Baseline Follow-up Baseline Follow-up
Health Mean Mean Mean tdf Mean Mean Mean tdf
Risk Factor (SD) (SD) Change (Pa) (SD) (SD) Change (Pa)
6-Month 6-Month 
Baseline Follow-up Signed Baseline Follow-up Signed
Median Median Mean Rank Sb Median Median Mean Rank Sb
(Range) (Range) Change (Pa) (Range) (Range) Change (Pa)
Table 5. Comparison of 6-Month Change in Mean Values of Health Risk Factors Among Intervention-Group (n = 174) and
Control-Group (n = 174) Participants in a Therapeutic Lifestyle-Modification Program
Body mass index –1.3 (–1.65 to –0.96) t320 = –7.39 (<.0001)
Weight, kg –3.9 (–5.0 to –2.8) t345 = –6.89 (<.0001)
Body fat, % –1.6 (–2.3 to –0.9) t321 = –4.60 (<.0001)
Systolic blood pressure, mm Hg –1 (–4 to 2) t342 = –0.66 (.51)
Diastolic blood pressure, mm Hg –1.7 (–3.5 to –0.0) t338 = –2.03 (.04)
Resting heart rate, beats/min –2.2 (–4.4 to –0.1) t334 = –2.19 (.03)
Glucose, mg/dL –2 (–6 to 0.4) t338 = –1.72 (.09)
Cholesterol, mg/dL –5 (–11 to 1) t338 = –1.79 (.08)
High-density lipoprotein, mg/dL –1.4 (–2.9 to –0.0) t338 = –2.01 (.045)
Low-density lipoprotein, mg/dL –4 (–9 to 2) t320 = –1.41 (.16)
Triglycerides, mg/dL –7 (–22 to 9) t338 = –0.83 (.40)
C-reactive protein, mg/dL –68.5 (–94 to 40) t326 = –0.80 (.42)
aSignificance for P values was determined using the Bonferroni correction and set at α = .0001.
Table 6. Health Risk Prevalence and Change in Mean Scores at 6-Month Follow-up Among Intervention-Group Participants (n
= 174) in a Therapeutic Lifestyle-Modification Program
Body mass index (kg/m2)
Underweight (<18.5) 0 (0.0) 1 (0.6) 4.0 (.04) —- —- —- —-
Normal (18.5-24.9) 24 (13.8) 36 (20.7) 22.74 21.90 –0.84 t24 = –2.25 (.03)
Overweight (25.0-29.9) 45 (25.9) 47 (27.0) 27.70 26.14 –1.56 t45 = –5.68 (<.0001)
Obese (>30.0) 105 (60.3) 90 (51.7) 38.16 36.35 –1.81 t104 = –10.21 (<.0001)
Systolic blood pressure (mm Hg)
Normal (<120) 52 (29.9) 76 (43.7) 5.0 (.02) 111.12 109.51 –1.61 t51 = –1.08 (.28)
Prehypertensive (120-139) 79 (45.4) 64 (36.8) 129.22 123.88 –5.34 t79 = –3.79 (.0002)
High (140-159) 35 (20.1) 28 (16.1) 147.56 137.60 –9.96 t35 = –4.71 (<.0001)
Dangerous (>160) 8 (4.6) 6 (3.4) 167.50 158.62 –8.88 t8 = –2.01 (.046)
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Change in Mean Values 
Health Risk Factor (95% Confidence Interval) tdf(P
a)
No. (%) of
No. (%) of Participants Baseline Follow-up 
Health Risk Participants at 6-Month Mean Meanc Mean 
Status at Baseline Follow-up X21
a(Pb) Score Score Change tdf(P
b)
(Continued on next page)aMantel-Haenszel chi-square test was used to test differences within risk status categories. 
bSignificance for P values was determined using the Bonferroni correction and set at α = .0001.
cFollow-up means are from the same individuals in each baseline risk category.
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Diastolic blood pressure (mm Hg)
Normal (<80) 97 (55.8) 131 (75.3) 15.2 71.90 68.09 –3.81 t96 = –4.75 (<.0001)
Prehypertensive (80-89) 55 (31.6) 35 (20.1) (<.0001) 83.31 78.58 –4.73 t55 = –4.36 (<.0001)
High (90-99) 20 (11.5) 7 (4.0) 93.25 76.80 –16.45 t20 = –9.15 (<.0001)
Dangerous (>100) 2 (1.2) 1 (0.6) —- —- —- —-
Total cholesterol (mg/dL)
Normal (<200) 105 (60.3) 94 (54.0) 1.6 (.20) 171.93 183.69 11.76 t103 = 4.58 (<.0001)
Borderline (200-239) 54 (31.0) 60 (34.5) 215.92 218.92 3.00 t54 = 0.94 (.35)
High risk (>240) 15 (8.6) 20 (11.5) 257.67 234.93 –22.74 t15 = –3.42 (.001)
Low-density lipoprotein (mg/dL)
Optimal (<100) 42 (24.1) 30 (17.2) 3.1 (.08) 85.02 103.07 18.05 t39 = 5.07 (<.0001)
Above optimal (100-129) 70 (40.2) 69 (39.7) 115.73 121.94 6.21 t68 = 2.43 (.02)
Borderline (130-159) 45 (25.9) 53 (30.5) 143.27 145.18 1.91 t45 = 0.61 (.54)
High (160-189) 14 (8.0) 17 (9.8) 172.64 151.43 –21.21 t14 = –3.81 (.0002)
Very high (>190) 3 (1.7) 5 (2.9) —- —- —- —-
High-density lipoprotein (mg/dL)
High (>60) 19 (10.9) 20 (11.5) 3.4 (.06) 69.16 68.21 –0.95 t19 = –0.64 (.52)
Normal (40-59) 84 (48.3) 104 (59.8) 48.52 48.78 0.26 t83 = 0.24 (.81)
Low (<40) 71 (40.8) 50 (28.7) 34.33 37.87 3.54 t70 = 4.43 (<.0001)
Triglycerides (mg/dL)
Normal (<150) 124 (71.3) 129 (74.1) 0.3 (.56) 88.68 100.05 11.37 t123 = 2.40 (.02)
Borderline (150-199) 25 (14.4) 22 (12.6) 171.52 152.58 –18.94 t24 = –1.65 (.10)
High (200-499) 23 (13.2) 22 (12.6) 283.22 238.30 –44.92 t23 = –4.06 (<.0001)
Very high (>500) 2 (1.2) 1 (0.6) —- —- —- —-
Glucose (mg/dL)
Normal (<110) 136 (78.2) 141 (81.0) 0.5 (.46) 93.67 92.77 –0.90 t135 = –0.78 (.44)
Impaired fasting glucose (110-125) 17 (9.8) 16 (9.2) 114.41 108.56 –5.85 t16 = –1.77 (.08)
Diabetes (>126) 21 (12.1) 17 (9.8) 152.00 137.90 –14.10 t21 = –4.85 (<.0001)
aMantel-Haenszel chi-square test was used to test differences within risk status categories. 
bSignificance for P values was determined using the Bonferroni correction and set at α = .0001.
cFollow-up means are from the same individuals in each baseline risk category.
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Table 6. (continued) Health Risk Prevalence and Change in Mean Scores at 6-Month Follow-up Among Intervention-Group
Participants (n = 174) in a Therapeutic Lifestyle-Modification Program
No. (%) of
No. (%) of Participants Baseline Follow-up 
Health Risk Participants at 6-Month Mean Meanc Mean 
Status at Baseline Follow-up X21
a(Pb) Score Score Change tdf(P
b)
Table 7. Health Risk Prevalence and Change in Mean Scores at 6-Month Follow-up Among Control-Group Participants (n =
174) in a Therapeutic Lifestyle-Modification Program
Body mass index (kg/m2)
Underweight (<18.5) 0 (0.0) 1 (0.6) 0.04 (.84) —- —- —- —-
Normal (18.5-24.9) 43 (24.7) 44 (25.3) 23.15 23.04 –0.11 t43 = –0.52 (.60)
Overweight (25.0-29.9) 56 (32.2) 54 (31.0) 27.42 27.10 –0.32 t55 = –1.55 (.12)
Obese (>30.0) 75 (43.1) 75 (43.1) 39.11 38.62 –0.49 t75 = –2.84 (.005)
Systolic blood pressure (mm Hg)
Normal (<120) 60 (34.5) 81 (46.6) 4.7 (.03) 111.07 109.67 –1.40 t60 = –0.92 (.36)
Prehypertensive (120-139) 69 (39.7) 64 (36.8) 128.72 123.52 –5.20 t68 = –3.58 (.0004)
High (140-159) 40 (23.0) 21 (12.1) 149.51 141.64 –7.87 t39 = –4.16 (<.0001)
Dangerous (>160) 5 (2.9) 8 (4.6) 165.40 157.00 –8.40 t5 = –1.59 (.11)
Diastolic blood pressure (mm Hg)
Normal (<80) 102 (58.6) 127 (73.0) 9.3 (.002) 70.55 68.08 –2.47 t101 = –3.25 (.001)
Prehypertensive (80-89) 52 (29.9) 40 (23.0) 82.21 77.83 –4.38 t52 = –4.25 (<.0001)
High (90-99) 18 (10.3) 5 (2.9) 93.33 84.61 –8.72 t18 = –4.98 (<.0001)
Dangerous (>100) 2 (1.2) 2 (1.2) —- —- —- —-
Total cholesterol (mg/dL)
Normal (<200) 107 (61.5) 86 (49.4) 6.7 (.01) 164.20 183.74 19.54 t102 = 6.40 (<.0001)
Borderline (200-239) 52 (29.9) 60 (34.5) 219.77 227.90 8.13 t51 = 2.04 (0.04)
High risk (>240) 15 (8.6) 28 (16.1) 260.47 236.67 –23.8 t15 = –3.14 (0.002)
Low-density lipoprotein (mg/dL)
Optimal (<100) 48 (27.6) 34 (19.5) 6.3 (.01) 81.43 100.38 18.95 t43 = 4.22 (<.0001)
Above optimal (100-129) 58 (33.3) 52 (29.9) 113.48 130.12 16.64 t57 = 5.18 (<.0001)
Borderline (130-159) 46 (26.4) 50 (28.7) 142.67 148.11 5.44 t46 = 1.54 (.13)
High (160-189) 17 (9.8) 32 (18.4) 170.35 169.06 –1.29 t16 = –0.28 (.78)
Very high (>190) 5 (2.9) 6 (3.4) —- —- —- —-
High-density lipoprotein (mg/dL)
High (>60) 16 (9.2) 24 (13.8) 5.2 (.02) 65.06 62.75 –2.31 t16 = –1.43 (.15)
Normal (40-59) 99 (56.9) 109 (62.6) 48.05 50.08 2.03 t98 = 3.27 (.001)
Low (<40) 59 (35.9) 41 (23.6) 33.87 39.84 5.97 t54 = 6.40 (<.0001)
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No. (%) of
No. (%) of Participants Baseline Follow-up 
Health Risk Participants at 6-Month Mean Meanc Mean 
Status at Baseline Follow-up X21
a(Pb) Score Score Change tdf(P
b)
(Continued on next page)aMantel-Haenszel chi-square test was used to test differences within risk status categories. 
bSignificance for P values was determined using the Bonferroni correction and set at α = .0001.
cFollow-up means are from the same individuals in each baseline risk category.
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Triglycerides (mg/dL)
Normal (<150) 138 (79.3) 131 (75.3) 0.7 (.40) 84.02 99.76 15.74 t132 = 3.23 (.002)
Borderline (150-199) 18 (10.3) 21 (12.1) 171.50 154.72 –16.78 t18 = –1.24 (.21)
High (200-499) 17 (9.8) 21 (12.1) 259.12 208.12 –51.00 t17 = –3.71 (.0003)
Very high (>500) 1 (0.6) 1 (0.57) —- —- —- —-
Glucose (mg/dL)
Normal (<110) 150 (86.2) 152 (87.4) 0.0 (.98) 94.64 94.41 –0.23 t146 = –2.98 (.77)
Impaired fasting glucose (110-125) 17 (9.8) 13 (7.5) 112.94 115.56 2.62 t16 = 0.68 (.50)
Diabetes (>126) 7 (4.0) 9 (5.2) 175.57 168.33 –7.24 t6 = –1.16 (.25)
aMantel-Haenszel chi-square test was used to test differences within risk status categories. 
bSignificance for P values was determined using the Bonferroni correction and set at α = .0001.
cFollow-up means are from the same individuals in each baseline risk category.
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Table 7. (continued) Health Risk Prevalence and Change in Mean Scores at 6-Month Follow-up Among Control-Group
Participants (n = 174) in a Therapeutic Lifestyle-Modification Program
No. (%) of
No. (%) of Participants Baseline Follow-up 
Health Risk Participants at 6-Month Mean Meanc Mean 
Status at Baseline Follow-up X21
a(Pb) Score Score Change tdf(P
b)
